Cancer is a major focus for Ipsen’s growth strategy, as evidenced by their expansion of oncology portfolio through recent business deals. An Ipsen employee, Dishant Gupta, has been charged with insider trading for allegedly profiting from stock transactions based on non-public information about Ipsen’s acquisition of a cancer drug developer. Gupta, who worked in data strategy and operations, allegedly accumulated shares of Epizyme leading up to the acquisition announcement, selling them for a profit of over $260,000. Ipsen’s oncology products drive most of their revenue, with multiple acquisitions and deals in the pipeline for cancer treatments. Gupta has agreed to plead guilty and faces penalties.
Source link
SEC Charges Ipsen Worker for Insider Trading Tied to $247M Epizyme Acquisition
